Advanced Oncotherapy (AVO) – Sinophi update
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has come to an agreement with Sinophi Healthcare Limited to terminate the purchase orders announced on 25 March 2015 and 21 October 2015. In addition, both parties have reached an agreement to terminate the distribution agreement also announced […]
Beaufort Securities view on Advanced Oncotherapy (AVO)
Beaufort Securities view on Advanced Oncotherapy (AVO). It always comes as a surprise when the market reacts violently to some news item whose impact was considered already to be priced-in. Yesterday’s announcement told shareholders nothing new. Back in November, AVO detailed the fact that Sinophi was no longer to proceed with the installation of LIGHT […]
Advanced Oncotherapy (AVO) – Sinophi Update
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment announces that on 23 January 2017, the Company was informed by Sinophi Healthcare Limited (“Sinophi”) that it wished to terminate the purchase orders announced on 25 March 2015 and 21 October 2015. Advanced Oncotherapy is firmly of the view that Sinophi has no […]
Advanced Oncotherapy (AVO) – Update on Harley Street and Sinophi
Advanced Oncotherapy – Update on Harley Street and Sinophi Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the building work for the Harley Street site is expected to start in early January with completion of the building works expected by March 2018. This follows the successful planning permission […]
Would you bet on the big names breaking into China? British firms beating a path to Beijing.
Would you bet on the big names breaking into China? British firms beating a path to Beijing. – by Ruth Sunderland – Daily Mail British businessmen in Beijing feel conditions are now right for UK companies to seize the upper hand over old rival Germany. Clare Pearson of the China Britain Business Council says: […]
Advanced Oncotherapy announces the appointment of an Executive Chairman at subsidiary ADAM
Advanced Oncotherapy announces that Professor Steve Myers OBE, Head of Medical Applications at CERN, has been appointed as Executive Chairman of Advanced Oncotherapy’s fully owned subsidiary ADAM S.A. ADAM was founded in 2007 as a spin-off from CERN, the European Organisation for Nuclear Research, and was acquired by Advanced Oncotherapy in 2013. The ADAM team […]
Advanced Oncotherapy announces the successful high power testing of two Coupled Cavity Linac (CCL) modules
Advanced Oncotherapy announces that the high power testing of two Coupled Cavity Linac (CCL) modules at the Company’s facility in Geneva has been successfully completed. In August the Company announced that the two CCL modules were ready to be tested at high power and marked the first time two CCL modules were tested together. The modules have […]